BeiGene pushes back on short seller report

BeiGene refuted claims by short seller J Capital that the company has reported “fake sales” of its cancer portfolio from Celgene.

John Oyler, CEO of BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160), told BioCentury, “It’s easy to see the short-seller report for what it is, a collection of misleading statements with malicious assumptions.”...